See HCG dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
HCG (human chorionic gonadotropin) functions as an LH mimetic, making it a widely researched compound for supporting testicular function and fertility during or after hormonal protocols. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their HCG reconstitution protocol.
Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone naturally secreted by the syncytiotrophoblast of the developing placenta in pregnancy, and the longest-clinically-established compound on this entire site. Its beta subunit is structurally distinct from luteinizing hormone (LH), but it shares an identical alpha subunit with LH, FSH, and TSH — and the high homology between the HCG and LH beta subunits means HCG binds and activates the LH/CG receptor (LHCGR) on Leydig cells in men and theca/granulosa cells in women. This LH-mimetic mechanism is the entire basis of HCG's clinical utility.
Human chorionic gonadotropin (hCG) is a glycoprotein hormone most often sourced for fertility and hormone-axis research. It has been an FDA-approved drug since the 1940s under brand names like Pregnyl, Novarel, and Ovidrel. Research-grade hCG ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
hCG shares its α-subunit with LH, FSH, and TSH but has a unique β-subunit that confers selectivity for the luteinizing-hormone/choriogonadotropin receptor (LHCGR). In males, LHCGR activation on testicular Leydig cells drives endogenous testosterone synthesis; in females, it triggers final oocyte maturation and ovulation. Because hCG acts upstream of the gonad rather than replacing testosterone directly, it preserves testicular volume and spermatogenesis — the basis of its use in fertility-preserving male hypogonadism protocols.
Beyond its long-established reproductive indications, hCG has been investigated as a maintenance therapy for spermatogenesis in men on testosterone-replacement therapy and as a fertility-restoration agent post-anabolic-steroid use. The FDA has formally rejected and warned against the use of hCG for weight loss (the Simeons "hCG diet"), citing the absence of evidence of efficacy and the risks of severely restricted caloric intake.
HCG has a reported half-life of ~33–36 hours (terminal), and the dose intervals researchers model most often fall around two to three times weekly. Long terminal half-life means hCG carries over meaningfully between injections, so a 2–3×/week or every-other-day cadence keeps levels reasonably stable. It is catalogued under Testosterone Peptides on WPA.
150 HCG reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (13 calculations). The median dose across all sessions is 500mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 5000mg (95 sessions). The most common dosing frequency is once weekly (22 logged protocols), followed by 2x/week (18).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.